Hypolipidemic drug clofibrate promotes hepatic tumor.
In diethylnitrosamine-initiated rats, administration of clofibrate for 32 weeks induced neoplastic lesions and hepatocellular carcinoma. In contrast to conventional carcinogens, clofibrate effected a marked decrease in the activity of gamma-glutamyltranspeptidase. Ornithine was selectively channeled into polyamine synthesis with concomitant repression of the urea cycle and the transamination pathway. These histological and biochemical studies suggest that clofibrate acts as a promoting agent in hepatocarcinogenesis.
Nagini
S
S
Dept. of Microbiology, Cancer Institute, Madras, India.
Nagarajan
B
B
D000818:Animals; D015197:Carcinogenicity Tests; D002994:Clofibrate / Q000633:toxicity*; D004052:Diethylnitrosamine / Q000633:toxicity; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced* / Q000201:enzymology / Q000473:pathology; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains
D004052:Diethylnitrosamine; D002994:Clofibrate